Sartorius preferred shares under fresh analyst scrutiny, Goldman and DZ Bank stay neutral
23.06.2026 - 21:52:02 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 21:49.
Sartorius Vz (DE0007165631) draws renewed attention from the analyst community. The preferred shares traded in Frankfurt face a cautious reassessment from Goldman Sachs and DZ Bank, with both houses keeping Neutral ratings on the German laboratory and bioprocess equipment supplier.
Goldman trims target, stays cautious
Goldman Sachs analyst James Quigley has lowered his 12-month price target for the Sartorius preferred shares from 230 euros to 229 euros and reiterated a Neutral rating, according to a flash note distributed via dpa-AFX on June 23, 2026.The dpa-AFX analysis flash on the Goldman Sachs study Quigley expects a muted second-quarter earnings report and points to historically elevated valuation levels for Sartorius relative to its own history.The same dpa-AFX flash details his cautious view
In his comments, Quigley highlights that management is likely to remain conservative and not raise full-year guidance with the upcoming second-quarter release, a stance that tempers expectations for near-term upside.The Goldman Sachs note as summarized by dpa-AFX The Sartorius preferred shares, which trade on Xetra and Frankfurt under ticker SRT3, recently changed hands around the low-210-euro area, implying only limited headroom to the revised Goldman target.Finanzen100 price overview for Sartorius Vz
DZ Bank reaffirms Neutral stance
Alongside Goldman Sachs, DZ Bank has also reiterated a Neutral view on the Sartorius preferred shares on June 23, 2026, keeping its rating unchanged according to MarketScreener’s analyst update feed.MarketScreener summary of the DZ Bank rating The DZ Bank note underscores the challenging valuation backdrop and a still-normalizing demand environment in bioprocess solutions, even as structural growth drivers in biopharmaceutical manufacturing remain intact.The same MarketScreener item outlines the reasoning
Both research houses therefore send a consistent message to investors: Sartorius remains a strategically important player in the bioprocess and lab equipment space, but near-term share price performance is constrained by valuation considerations and the lack of a clear upside catalyst before the next quarterly report.MarketScreener also covers the Goldman stance on Sartorius Vz Consensus data compiled by MarketScreener show an average target price around 266 euros for the preferred shares, indicating that several houses remain more constructive, but the fresh Neutral reiterations by Goldman and DZ Bank inject a more cautious tone into the mix.MarketScreener consensus figures on Sartorius
Background and price data on Sartorius preferred shares
For a broader view on the Sartorius Vz shares, including historical performance, additional analyst opinions and upcoming events, the following resources offer consolidated data and official company information.
The business behind the shares
Sartorius generates its revenues primarily through bioprocess solutions and laboratory products used by biopharmaceutical manufacturers and research labs worldwide, with a strong operational base in Göttingen, Germany.MarketScreener describes Sartorius as a supplier of pharmaceutical and laboratory equipment The bioprocess solutions segment offers single-use bioreactors, filtration systems and fluid management technologies that support the manufacture of vaccines, monoclonal antibodies and other biologics.Product segment descriptions from MarketScreener
The lab products and services segment provides precision balances, pipettes, water purification systems and consumables that are integral to daily workflows in academic, industrial and clinical laboratories.The same source lists typical lab products With this portfolio, Sartorius sits alongside peers such as Thermo Fisher Scientific and Danaher’s Cytiva business in the global life science tools sector, serving customers across drug discovery, development and commercial manufacturing.
Where the Sartorius preferred shares trade today
The Sartorius preferred shares (DE0007165631) trade on Xetra and Frankfurt under ticker SRT3, with recent indicative prices around 214 to 215 euros per share as of June 23, 2026, in euros.MarketScreener’s real-time estimate for Sartorius Vz
Key data on the Sartorius preferred shares
- Company: Sartorius Aktiengesellschaft
- ISIN: DE0007165631
- WKN: 716563
- Ticker: SRT3
- Trading venue: Xetra / Frankfurt
- Price (as of 2026-06-23, 21:49): 214.75 EUR
- Market cap: approximately 15 billion EUR (as of 2026-06-23)
- Sector / industry: Life science tools and services / pharmaceutical and laboratory equipment
- Index membership: DAXsector Pharma & Healthcare Performance-Index
- Next earnings date: not officially scheduled
Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any financial instrument. Figures and assessments reflect the sources cited as of the stated dates and may change over time.
